SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

An iPSC model of hereditary sensory neuropathy-1 reveals L-serine-responsive deficits in neuronal ganglioside composition and axoglial interactions.

Clark, AJ; Kugathasan, U; Baskozos, G; Priestman, DA; Fugger, N; Lone, MA; Othman, A; Chu, KH; Blesneac, I; Wilson, ER; et al. Clark, AJ; Kugathasan, U; Baskozos, G; Priestman, DA; Fugger, N; Lone, MA; Othman, A; Chu, KH; Blesneac, I; Wilson, ER; Laurà, M; Kalmar, B; Greensmith, L; Hornemann, T; Platt, FM; Reilly, MM; Bennett, DL (2021) An iPSC model of hereditary sensory neuropathy-1 reveals L-serine-responsive deficits in neuronal ganglioside composition and axoglial interactions. Cell Rep Med, 2 (7). p. 100345. ISSN 2666-3791 https://doi.org/10.1016/j.xcrm.2021.100345
SGUL Authors: Blesneac, Iulia

[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution.

Download (5MB) | Preview

Abstract

Hereditary sensory neuropathy type 1 (HSN1) is caused by mutations in the SPTLC1 or SPTLC2 sub-units of the enzyme serine palmitoyltransferase, resulting in the production of toxic 1-deoxysphingolipid bases (DSBs). We used induced pluripotent stem cells (iPSCs) from patients with HSN1 to determine whether endogenous DSBs are neurotoxic, patho-mechanisms of toxicity and response to therapy. HSN1 iPSC-derived sensory neurons (iPSCdSNs) endogenously produce neurotoxic DSBs. Complex gangliosides, which are essential for membrane micro-domains and signaling, are reduced, and neurotrophin signaling is impaired, resulting in reduced neurite outgrowth. In HSN1 myelinating cocultures, we find a major disruption of nodal complex proteins after 8 weeks, which leads to complete myelin breakdown after 6 months. HSN1 iPSC models have, therefore, revealed that SPTLC1 mutation alters lipid metabolism, impairs the formation of complex gangliosides, and reduces axon and myelin stability. Many of these changes are prevented by l-serine supplementation, supporting its use as a rational therapy.

Item Type: Article
Additional Information: © 2021 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: 1-deoxySLBs, DSBs, HSN1, SPT, SPTLC1, axon, ganglioside, hereditary sensory neuropathy type 1, l-serine, myelin, sensory neuron, serine palmitoyltransferase, serine palmitoyltransferase long-chain base subunit 1, sphingolipid
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE )
Journal or Publication Title: Cell Rep Med
ISSN: 2666-3791
Language: eng
Dates:
DateEvent
21 July 2021Published Online
20 July 2021Published
15 June 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
202747/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
115439Innovative Medicines Joint InitiativeUNSPECIFIED
NNF14SA0006Novo Nordisk FoundationUNSPECIFIED
519779Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
31003ASwiss National FoundationUNSPECIFIED
U54NS065712Office of Rare Diseases ResearchUNSPECIFIED
MDA510281Muscular Dystrophy Associationhttp://dx.doi.org/10.13039/100005202
203141/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 34337561
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113556
Publisher's version: https://doi.org/10.1016/j.xcrm.2021.100345

Actions (login required)

Edit Item Edit Item